Funding to stop Candida auris lacking

A high proportion of people who have been diagnosed with C. auris have died


Scientists who work in mycology — the study of fungi — say there is precious little money available to study Candida auris, according to an article on the STAT News website.

Candida auris is making news for its ability to resist multiple antifungal drugs and settle into hospital rooms so persistently it can take renovations to get rid of it.

The head of mycotic diseases at the Centers for Disease Control and Prevention (CDC) acknowledged his field hasn’t attracted the same kind of research dollars as other pathogens.

A high proportion of people who have been diagnosed with C. auris have died — the CDC estimates it’s between 30 percent and 60 percent.

Read the article.



July 16, 2019


Topic Area: Infection Control


Recent Posts

Barriers to Infection: Rethinking Mattress Cleaning

Laundering removable bed barriers provides a more effective, consistent and safer method for eliminating harmful bacteria compared to manual cleaning.


Over 1 Million Individuals Affected in Community Health Center Data Breach

No evidence of data misuse has been found so far.


Prospect Medical Holdings to Sell Crozer Health to Non-Profit Consortium

The sale includes Crozer Health’s operating assets, including all hospitals, ambulatory surgery centers, clinics and physician offices.


The Top States for Pest Infestations

Healthcare facilities are among the most popular locations for pest infestations.


Ground Broken on Wichita Biomedical Campus Project

The $172.5-million, eight-story, 350,000-square-foot building is expected to open in 2027.


 
 


FREE Newsletter Signup Form

News & Updates | Webcast Alerts
Building Technologies | & More!

 
 
 


All fields are required. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

 
 
 
 

Healthcare Facilities Today membership includes free email newsletters from our facility-industry brands.

Facebook   Twitter   LinkedIn   Posts

Copyright © 2023 TradePress. All rights reserved.